Abstract: Since a few hundred years microscopy has been the choice tool for microbiologists studying host-pathogen cell biology unmatched in its ability to resolve cell/tissue-morphology, dynamics, behavior, and interactions. Today, driven by advances in lab-automation, computer vision, and light detection technologies imaging-microscopy is at the cutting-edge in the form of "High-Content Screening" (HCS; a.k.a. Phenotypic Screening). Using mainly imaging based technologies to quantify in situ functional, and morphological parameters measured normally from intact, if not living cells, HCS is emerging a powerful tool for early drug discovery. New methodological and technological approaches in photonic imaging hold promise to improve HCS enabling analyses with more relevant biological paradigms, associated with infection, inflammation and immune response. Further innovations in micro-fluidics, biobanking, and single-cell transcriptomics are raising even higher expectations for the utility of HCS in experimental biology, and drug discovery. This presentation will discuss some of the challenges we perceive in perspective of the future at the Institut Pasteur (Korea, Paris, and worldwide) wherein our dedicated Phenotypic Screening Platforms for Infectious Diseases have for over fifteen years been leading the way in HCS for infectious disease.
Keywords: imaging, infection, multi-dimensional, microscopy, luminescence.